Security
Petra Acquisition Inc. Units · PAICU
PAICUNASDAQUnitHistorical · closed Jan 10, 2022CIK 1810560Updated Oct 6, 2026
Name history
Petra Acquisition Inc. · through Jan 11, 2022
Current security for this SEC filerREVB · NASDAQ
PAICU price & chart
Historical security
This listing closed Jan 10, 2022. Live provider charts are shown only for current listings.
Current security: REVB
About the company
Revelation is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. We have multiple ongoing programs to evaluate Gemini, including GEM-AKI as a prevention for acute kidney injury (“AKI”), GEM-CKD as a treatment for chronic kidney disease (“CKD”), GEM-PSI as a prevention for post surgical infection (“PSI”), and GEM-PBI as a prevention of infection in severe burn patients requiring hospitalization (“PBI”). The Company was incorporated in the state of Delaware on November 20, 2019 (originally as Petra Acquisition, Inc.) and is based in San Diego, California.
In the news
No coverage from other publishers is available.
Recent filings
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02, 9.01
4 filing
4 filing
4 filing
4 filing
Show 5 more recent filings
SCHEDULE 13G/A - filed by ARMISTICE CAPITAL, LLC regarding REVELATION BIOSCIENCES, INC.
Results of Operations and Financial Condition
Items 2.02, 9.01
10-Q filing
8-A12B filing
Entry into a Material Definitive Agreement · Material Modification to Rights of Security Holders · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Regulation FD Disclosure
Items 1.01, 3.03, 5.03, 7.01, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 12,856,342Source | 6,740,140Source | 12,497,932Source | 5,395,090Source | 12,269,575Source | 15,044,282Source | 3,970,271Source | 14,701,610Source | 11,582,924Source | 6,622,049Source | 12,212,609Source | 5,503,415Source |
| Property, Plant and Equipment, NetUSD | 23,919Source | 81,242Source | 172,032Source | 35,170Source | 70,774Source | 140,717Source | 42,390Source | 77,994Source | 18,067Source | 56,332Source | 65,084Source | 90,133Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 12,708,489Source | 6,541,052Source | 11,482,792Source | 5,173,871Source | 12,073,058Source | 14,113,415Source | 3,704,611Source | 14,551,740Source | 10,700,331Source | 6,499,018Source | 11,991,701Source | 5,252,979Source |
| Assets, CurrentUSD | 12,832,423Source | 6,658,898Source | 11,684,516Source | 5,359,920Source | 12,198,801Source | 14,206,035Source | 3,927,881Source | 14,623,616Source | 10,811,628Source | 6,565,717Source | 12,147,525Source | 5,413,282Source |
| Prepaid Expense and Other Assets, CurrentUSD | 123,934Source | 117,846Source | 201,724Source | 186,049Source | 125,743Source | 92,620Source | 223,270Source | 71,876Source | 111,297Source | 66,699Source | 84,691Source | 73,132Source |
| Operating Lease, Right-of-Use AssetUSD | — | — | 610,443Source | — | — | 666,589Source | — | — | 722,288Source | — | — | — |
| Other Assets, NoncurrentUSD | — | — | 30,941Source | — | — | 30,941Source | — | — | 30,941Source | — | — | — |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 1,854,507Source | 4,066,523Source | 2,430,946Source | 1,569,306Source | 11,129,154Source | 2,055,329Source | 1,089,519Source | 5,228,465Source | 2,721,929Source | 1,913,667Source | 5,564,894Source | 4,450,962Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 3,586Source | 4,292Source | 3,908Source | 1,535Source | 1,643Source | 3,908Source | 964Source | 1,633Source | 1,584Source | 522Source | 265Source | 683Source |
| Additional Paid in CapitalUSD | 57,906,530Source | 41,449,244Source | 65,814,800Source | 48,825,354Source | 37,677,132Source | 65,413,383Source | 45,436,511Source | 37,620,047Source | 58,278,698Source | 45,213,498Source | 32,114,552Source | 26,398,618Source |
| Retained Earnings (Accumulated Deficit)USD | -46,908,281Source | -38,779,919Source | -55,751,722Source | -45,001,105Source | -36,538,354Source | -52,428,338Source | -42,556,723Source | -28,148,535Source | -49,419,287Source | -40,505,638Source | -25,467,102Source | -25,346,848Source |
| Stockholders' Equity Attributable to ParentUSD | 11,001,835Source | 2,673,617Source | 10,066,986Source | 3,825,784Source | 1,140,421Source | 12,988,953Source | 2,880,752Source | 9,473,145Source | 8,860,995Source | 4,708,382Source | 6,647,715Source | 1,052,453Source |
| Liabilities and EquityUSD | 12,856,342Source | 6,740,140Source | 12,497,932Source | 5,395,090Source | 12,269,575Source | 15,044,282Source | 3,970,271Source | 14,701,610Source | 11,582,924Source | 6,622,049Source | 12,212,609Source | 5,503,415Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 1,854,507Source | 4,066,523Source | 1,880,400Source | 1,569,306Source | 11,129,154Source | 1,417,146Source | 1,089,519Source | 5,228,465Source | 1,998,158Source | 1,913,667Source | 5,564,894Source | 4,450,962Source |
| Operating Lease, Liability, CurrentUSD | — | — | 189,370Source | — | — | 120,861Source | — | — | 23,013Source | — | — | — |
| Accounts Payable, CurrentUSD | 1,034,951Source | 3,127,348Source | 931,093Source | 828,894Source | 1,281,323Source | 828,203Source | 625,058Source | 1,681,665Source | 577,501Source | 783,621Source | 1,359,898Source | 554,205Source |
| Operating Lease, Liability, NoncurrentUSD | — | — | 550,546Source | — | — | 638,183Source | — | — | 723,771Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 819,381Source | 934,372Source | 759,937Source | 739,626Source | 8,454,139Source | 468,082Source | 463,632Source | 620,280Source | 1,397,644Source | 1,127,800Source | 1,152,460Source | 985,497Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 470,997Source | 223,455Source | 595,368Source | 168,850Source | 155,721Source | 301,116Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 216,900Source | -158,563Source | -206,120Source | -576,277Source | 749,660Source | -666,042Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -3,214,851Source | -2,794,407Source | -8,269,581Source | -18,321,276Source | -7,286,286Source | -11,219,396Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -71,879Source | — | — | -19,171Source | — | — |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 71,879Source | — | — | 19,171Source | — | — |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 6,699,814Source | — | 12,470,894Source | 12,847,764Source | 14,025,008Source | 15,197,646Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 12,708,489Source | 6,541,052Source | 11,482,792Source | 5,173,871Source | 14,113,415Source | 3,704,611Source | 10,700,331Source | 6,499,018Source | 11,991,701Source | 5,252,979Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 874Source | 32,095Source | 401,417Source | 873Source | 470,997Source | 223,455Source | 595,368Source | 168,850Source | 155,721Source | 301,116Source |
| DepreciationUSD | — | — | — | — | 8,313Source | 7,220Source | 7,203Source | 7,221Source | 27,058Source | 27,923Source | 25,049Source | 25,048Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | — | — | -11,207Source | — | — | — |
| General and Administrative ExpenseUSD | — | — | 1,020,154Source | 965,705Source | 1,743,817Source | 1,143,249Source | 1,715,639Source | 1,236,157Source | 5,006,957Source | 4,426,113Source | 4,510,762Source | 5,487,111Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | — | — | — | 0Source | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -1,907,176Source | -2,241,565Source | -3,323,384Source | -2,444,382Source | -3,009,051Source | -2,051,085Source | -8,913,649Source | -15,038,536Source | -120,254Source | -10,829,549Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -4,676,918Source | -2,241,565Source | -3,323,384Source | -5,626,168Source | -8,690,667Source | -2,051,085Source | -14,865,177Source | — | — | — |
| Nonoperating Income (Expense)USD | — | — | 35,835Source | -444,879Source | 338,857Source | 16,847Source | 83,449Source | 43,902Source | 157,165Source | -7,063,427Source | 8,536,410Source | 34,962Source |
| Operating ExpensesUSD | — | — | 1,943,011Source | 1,796,686Source | 3,662,241Source | 2,461,229Source | 3,092,500Source | 2,094,987Source | 9,070,814Source | 7,975,109Source | 8,656,664Source | 10,864,511Source |
| Operating Lease, ExpenseUSD | — | — | — | 16,050Source | — | — | — | — | — | 64,200Source | 111,661Source | 66,645Source |
| Other Nonoperating Income (Expense)USD | — | — | 35,224Source | -450,920Source | 338,857Source | 16,803Source | 83,449Source | 42,485Source | 155,007Source | -7,144,868Source | 207,473Source | 34,962Source |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | — | -1,943,011Source | -1,796,686Source | -3,662,241Source | -2,461,229Source | -3,092,500Source | -2,094,987Source | -9,070,814Source | -7,975,109Source | -8,656,664Source | -10,864,511Source |
| Other Nonoperating Income (Expense)USD | — | — | 35,224Source | -450,920Source | 338,857Source | 16,803Source | 83,449Source | 42,485Source | 155,007Source | -7,144,868Source | 207,473Source | 34,962Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | — | — | — | 0Source | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -1,907,176Source | -2,241,565Source | -3,323,384Source | -2,444,382Source | -3,009,051Source | -2,051,085Source | -8,913,649Source | -15,038,536Source | -120,254Source | -10,829,549Source |
| Earnings Per Share, BasicUSD per share | — | — | — | — | -0.87Source | -28.04Source | -2.71Source | -25.34Source | -23.95Source | -87.68Source | -0.53Source | -20.09Source |
| Earnings Per Share, DilutedUSD per share | — | — | — | — | -0.87Source | -28.04Source | -2.71Source | -25.34Source | -23.95Source | -87.68Source | -0.53Source | -20.09Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | — | — | 3,829,363Source | 200,668Source | 3,207,720Source | 80,943Source | 620,785Source | 171,510Source | 228,641Source | 539,037Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | — | — | 3,829,363Source | 200,668Source | 3,207,720Source | 80,943Source | 620,785Source | 171,510Source | 228,641Source | 539,037Source |
| Additional Financial Items | ||||||||||||
| General and Administrative ExpenseUSD | — | — | 1,020,154Source | 965,705Source | 1,743,817Source | 1,143,249Source | 1,715,639Source | 1,236,157Source | 5,006,957Source | 4,426,113Source | 4,510,762Source | 5,487,111Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -4,676,918Source | -2,241,565Source | -3,323,384Source | -5,626,168Source | -8,690,667Source | -2,051,085Source | -14,865,177Source | — | — | — |
| Nonoperating Income (Expense)USD | — | — | 35,835Source | -444,879Source | 338,857Source | 16,847Source | 83,449Source | 43,902Source | 157,165Source | -7,063,427Source | 8,536,410Source | 34,962Source |
| Operating ExpensesUSD | — | — | 1,943,011Source | 1,796,686Source | 3,662,241Source | 2,461,229Source | 3,092,500Source | 2,094,987Source | 9,070,814Source | 7,975,109Source | 8,656,664Source | 10,864,511Source |
| Operating Lease, ExpenseUSD | — | — | — | 16,050Source | — | — | — | — | — | 64,200Source | 111,661Source | 66,645Source |
| Research and Development ExpenseUSD | — | — | 922,857Source | 830,981Source | 1,918,424Source | 1,317,980Source | 1,376,861Source | 858,830Source | 4,063,857Source | 3,548,996Source | 4,145,902Source | 5,377,400Source |
| Interest Income (Expense), Net | — | — | — | — | —Source | —Source | — | — | — | — | — | — |
Offerings
Registration 333-293078
Registration 333-287423
Filing attachments
revb-ex99_1.htm · 8-K · 2026-08-06
EX-99.1 2 revb-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Revelation Biosciences, Inc. Announces Financial Results For the Three and Six Months Ended June 30, 2026 SAN DIEGO - August 6, 2026 - Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company developing innovative solutions to treat acute and chronic disease, today reported its financial results for the three and six months ended June 30, 2026. Corporate Highlights • Announ…
Read attachment ↗revb-ex4_1.htm · 8-K · 2026-07-13
EX-4.1 3 revb-ex4_1.htm EX-4.1 EX-4.1 Exhibit 4.1 RIGHTS AGREEMENT dated as of July 10, 2026 by and between REVELATION BIOSCIENCES, INC. and CONTINENTAL STOCK TRANSFER & TRUST CO. Table of Contents SECTION 1. Certain Definitions 3 SECTION 2. Appointment of Rights Agent 10…
Read attachment ↗revb-ex99_1.htm · 8-K · 2026-07-13
EX-99.1 4 revb-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Revelation Biosciences Announces Adoption of Stockholder Rights Plan SAN DIEGO - July 10, 2026 - Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company developing innovative solutions to treat acute and chronic disease, today announced that its Board of Directors (the “Board”) has adopted a stockholder rights plan (the “Rights Plan”) and declared a dividend distribution of o…
Read attachment ↗revb-ex99_1.htm · 8-K · 2026-05-07
EX-99.1 2 revb-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Revelation Biosciences, Inc. Announces Financial Results For the Three Months Ended March 31, 2026 SAN DIEGO - May 7, 2026 - Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company developing innovative solutions to treat acute and chronic disease, today reported its financial results for the three months ended March 31, 2026. Corporate Highlights • Announced agreement wit…
Read attachment ↗revb-ex99_1.htm · 8-K · 2026-02-26
EX-99.1 2 revb-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Revelation Biosciences, Inc. Announces Financial Results For the Three and Twelve Months Ended December 31, 2025 SAN DIEGO - February 26, 2026 - Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company focused on rebalancing inflammation to optimize health, today reported its financial results for the three and twelve months ended December 31, 2025. Corporate Highlights • A…
Read attachment ↗